{"classes":[{"categories":[{"measurements":[{"comment":"SD cannot be calculated as only one participant was analyzed.","groupId":"OG000","spread":"NA","value":"141.32217"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Participant 1"},{"categories":[{"measurements":[{"comment":"SD cannot be calculated as only one participant was analyzed.","groupId":"OG000","spread":"NA","value":"121.45383"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Participant 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Serum concentration of cetrelimab were reported.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with CIS with or without papillary disease, received cetrelimab 360 mg IV Q3W from Week 0 through Week 78.","id":"OG000","title":"Cohort 3: Cetrelimab IV Monotherapy (CIS With or Without Papillary Disease)"}],"paramType":"MEAN","populationDescription":"FAS included all enrolled participants who received at least 1 dose of study treatment. Here \"N\" (overall number of participants analyzed) signifies number of participants evaluable for this outcome measure, \"n\" (number analyzed) signifies number of participants evaluable at specific timepoints. Per plan, data was not summarized when overall number of participants analyzed was less than 3. Therefore, participant wise data is reported.","reportingStatus":"POSTED","timeFrame":"At Weeks 60 (EOI)","title":"Cohort 3: Serum Concentration of Cetrelimab","type":"SECONDARY","unitOfMeasure":"mcg/mL"}